Lacosamide Accord

Lacosamide, the active ingredient in Lacosamide Accord, is an antiepileptic presented as an oral tablet for oral use. It is employed as adjunctive therapy for partial‑onset (focal) seizures in patients with epilepsy. The medication is formulated according to European Union pharmaceutical standards and is supplied in a tablet dosage that facilitates consistent daily administration. Its pharmacokinetic profile allows once‑ or twice‑daily dosing, and it is well‑absorbed from the gastrointestinal tract. The product does not contain any controlled substances and is classified as prescription‑only.

GNH USA supplies Lacosamide Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacosamide is an antiepileptic drug that acts on neuronal sodium channels to control seizure activity.

Partial‑onset seizures (adjunctive therapy): Reduces seizure frequency when added to existing antiepileptic regimens. Focal seizures (adjunctive therapy): Provides additional seizure control for patients not fully controlled by other medications.

Lacosamide may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Nausea: mild gastrointestinal upset often occurring early in treatment. - Dizziness: transient feeling of light‑headedness, especially after dose escalation. - Headache: mild to moderate tension‑type headaches. - Fatigue: general tiredness that may improve with continued use.

Serious or Rare Side Effects: - Cardiac conduction abnormalities: PR‑interval prolongation or atrioventricular block, requiring ECG monitoring in susceptible patients. - Severe skin reactions: rare cases of Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Suicidal thoughts: rare emergence of mood changes or suicidal ideation, necessitating psychiatric assessment.

When prescribing Lacosamide, clinicians should consider several precautionary measures to ensure safe use. - Cardiac monitoring: obtain baseline ECG and monitor PR interval in patients with cardiac disease. - Renal impairment: adjust dose or monitor levels in patients with severe renal dysfunction. - Concomitant CNS depressants: use caution as additive dizziness or somnolence may occur. - Pregnancy: limited data; avoid use unless potential benefit justifies potential risk. - Store below 25°C: keep in the original packaging, protect from moisture and light.

Lacosamide can interact with other medicines, affecting its concentration or cardiac effects.

Major Interactions (Avoid): - Class III antiarrhythmics (e.g., amiodarone, sotalol): may exacerbate PR‑interval prolongation. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase lacosamide plasma levels, raising toxicity risk.

Moderate Interactions (Monitor Closely): - Carbamazepine or phenytoin: enzyme inducers that may lower lacosamide concentrations. - Opioids (e.g., tramadol, oxycodone): additive CNS depression. - Alcohol: may enhance dizziness and sedation.